文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

非编码 RNA 在癌症治疗耐药性和靶向药物研发中的作用。

Noncoding RNAs in cancer therapy resistance and targeted drug development.

机构信息

MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory for Biocontrol, Sun Yat-sen University, Guangzhou, 510275, China.

School of Life Science, Sun Yat-sen University, Guangzhou, 510275, People's Republic of China.

出版信息

J Hematol Oncol. 2019 Jun 7;12(1):55. doi: 10.1186/s13045-019-0748-z.


DOI:10.1186/s13045-019-0748-z
PMID:31174564
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6556047/
Abstract

Noncoding RNAs (ncRNAs) represent a large segment of the human transcriptome and have been shown to play important roles in cellular physiology and disease pathogenesis. Increasing evidence on the functional roles of ncRNAs in cancer progression emphasizes the potential of ncRNAs for cancer treatment. Here, we summarize the roles of ncRNAs in disease relapse and resistance to current standard chemotherapy and radiotherapy; the current research progress on ncRNAs for clinical and/or potential translational applications, including the identification of ncRNAs as therapeutic targets; therapeutic approaches for ncRNA targeting; and ncRNA delivery strategies in potential clinical translation. Several ongoing clinical trials of novel RNA-based therapeutics were also emphasized. Finally, we discussed the perspectives and obstacles to different target combinations, delivery strategies, and system designs for ncRNA application. The next approved nucleic acid drug to treat cancer patients may realistically be on the horizon.

摘要

非编码 RNA(ncRNAs)是人类转录组的重要组成部分,它们在细胞生理学和疾病发病机制中发挥着重要作用。越来越多的证据表明,ncRNAs 在癌症进展中的功能作用强调了 ncRNAs 在癌症治疗中的潜力。在这里,我们总结了 ncRNAs 在疾病复发和对当前标准化疗和放疗的耐药性中的作用;目前关于 ncRNAs 的临床和/或潜在转化应用的研究进展,包括将 ncRNAs 鉴定为治疗靶点;针对 ncRNA 的治疗方法;以及 ncRNA 在潜在临床转化中的递药策略。还强调了几种正在进行的新型基于 RNA 的治疗药物的临床试验。最后,我们讨论了不同的靶点组合、递药策略和系统设计用于 ncRNA 应用的前景和障碍。下一个被批准用于治疗癌症患者的核酸药物可能即将面世。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/650d/6556047/5911a03cf7b9/13045_2019_748_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/650d/6556047/f578f91f52ff/13045_2019_748_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/650d/6556047/0ea8f43618f9/13045_2019_748_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/650d/6556047/d72665a74b39/13045_2019_748_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/650d/6556047/5911a03cf7b9/13045_2019_748_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/650d/6556047/f578f91f52ff/13045_2019_748_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/650d/6556047/0ea8f43618f9/13045_2019_748_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/650d/6556047/d72665a74b39/13045_2019_748_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/650d/6556047/5911a03cf7b9/13045_2019_748_Fig4_HTML.jpg

相似文献

[1]
Noncoding RNAs in cancer therapy resistance and targeted drug development.

J Hematol Oncol. 2019-6-7

[2]
Therapeutic targeting of non-coding RNAs in cancer.

Biochem J. 2017-12-14

[3]
Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.

Adv Exp Med Biol. 2016

[4]
Cardiovascular RNA interference therapy: the broadening tool and target spectrum.

Circ Res. 2013-8-16

[5]
NoncoRNA: a database of experimentally supported non-coding RNAs and drug targets in cancer.

J Hematol Oncol. 2020-2-28

[6]
The emerging role of super enhancer-derived noncoding RNAs in human cancer.

Theranostics. 2020

[7]
Noncoding RNAs in Therapeutic Resistance of Cancer.

Adv Exp Med Biol. 2016

[8]
MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

Nat Rev Drug Discov. 2013-11

[9]
Role of non-coding RNAs mediated pyroptosis on cancer therapy: a review.

Expert Rev Anticancer Ther. 2024-5

[10]
Roles of noncoding RNAs in drug resistance in multiple myeloma.

J Cell Physiol. 2020-11

引用本文的文献

[1]
Engineered exosomes: a promising design platform for overcoming cancer therapy resistance.

Front Cell Dev Biol. 2025-8-6

[2]
Integrative Genomic and Functional Approaches Identify FUOM as a Key Driver and Therapeutic Target in Cervical Cancer.

Cancer Rep (Hoboken). 2025-8

[3]
Identification of novel biomarkers involved in oral squamous cell carcinoma by whole transcriptome sequencing and bioinformatics analysis.

Cancer Cell Int. 2025-7-22

[4]
Exosomal delivery of non-coding RNAs: a pathway to apoptosis regulation in lung cancer.

Med Oncol. 2025-7-1

[5]
Non-coding RNAs as key players in neurodegeneration and brain tumors: Insights into therapeutic strategies.

Iran J Basic Med Sci. 2025

[6]
Regulatory role of non-coding RNAs in 5-Fluorouracil resistance in gastrointestinal cancers.

Cancer Drug Resist. 2025-1-16

[7]
Diagnostic and therapeutic role of non-coding RNAs regulating programmed cell death in melanoma.

Front Oncol. 2024-12-24

[8]
Relationship between circulating miRNA-222-3p and miRNA-136-5p and the efficacy of docetaxel chemotherapy in metastatic castration-resistant prostate cancer patients.

BMC Urol. 2024-12-21

[9]
Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies.

Cancer Cell Int. 2024-12-19

[10]
Shared and specific competing endogenous RNAs network mining in four digestive system tumors.

Comput Struct Biotechnol J. 2024-11-5

本文引用的文献

[1]
The Landscape of Circular RNA in Cancer.

Cell. 2019-2-7

[2]
hsa_circ_0081143 promotes cisplatin resistance in gastric cancer by targeting miR-646/CDK6 pathway.

Cancer Cell Int. 2019-2-1

[3]
Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance.

Mol Ther. 2019-1-7

[4]
Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin.

Biomaterials. 2018-11-30

[5]
Antisense Oligonucleotide-Conjugated Nanostructure-Targeting lncRNA MALAT1 Inhibits Cancer Metastasis.

ACS Appl Mater Interfaces. 2018-12-18

[6]
RNA therapy: Are we using the right molecules?

Pharmacol Ther. 2018-12-4

[7]
Circular RNA hsa_circ_0004015 regulates the proliferation, invasion, and TKI drug resistance of non-small cell lung cancer by miR-1183/PDPK1 signaling pathway.

Biochem Biophys Res Commun. 2018-11-30

[8]
Long non-coding RNAs in hematological malignancies: translating basic techniques into diagnostic and therapeutic strategies.

J Hematol Oncol. 2018-11-22

[9]
Cancer-associated Fibroblast-promoted LncRNA Confers Radioresistance by Regulating DNA Damage Response in Esophageal Squamous Cell Carcinoma.

Clin Cancer Res. 2018-11-21

[10]
Knockdown of Long Non-Coding RNA XIST Inhibited Doxorubicin Resistance in Colorectal Cancer by Upregulation of miR-124 and Downregulation of SGK1.

Cell Physiol Biochem. 2018

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索